Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance CIK Cells for SCLC
NCT01592422Phase 2Unknown
- Sponsor
- Guangxi Zhuang Autonomous Region People's Hospital
- Start
- Jul 2012
- Primary completion
- Jul 2015
- Modality
- Prophylactic Vaccines, Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
A Phase 2 trial of autologous cytokine-induced killer cells in small cell lung cancer (SCLC), sponsored by Guangxi Zhuang Autonomous Region People's Hospital. Status: unknown.
02
Drugs
autologous cytokine-induced killer cells
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01592422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01592422.